Publication:
Cancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges.

Simple item page
dc.contributor.authorLÜ, J
dc.contributor.authorZHANG, J
dc.contributor.authorJIANG, C
dc.contributor.authorDENG, Y
dc.contributor.authorÖzten, NUR
dc.contributor.authorBOSLAND, MC
dc.contributor.institutionauthorÖZTEN KANDAŞ, NUR
dc.date.accessioned2019-10-05T13:48:16Z
dc.date.available2019-10-05T13:48:16Z
dc.date.issued2016-01-01
dc.description.abstractThe negative efficacy outcomes of double-blinded, randomized, placebo-controlled Phase III human clinical trials with selenomethionine (SeMet) and SeMet-rich selenized-yeast (Se-yeast) for prostate cancer prevention and Se-yeast for prevention of non-small cell lung cancer (NSCLC) in North America lead to rejection of SeMet/Se-yeast for cancer prevention in Se-adequate populations. We identify two major lessons from the outcomes of these trials: 1) The antioxidant hypothesis was tested in wrong subjects or patient populations. 2) The selection of Se agents was not supported by cell culture and preclinical animal efficacy data as is common in drug development. We propose that next-generation forms of Se (next-gen Se), such as methylselenol precursors, offer biologically appropriate approaches for cancer chemoprevention but these are faced with formidable challenges. Solid mechanism-based preclinical efficacy assessments and comprehensive safety studies with next-gen Se will be essential to re-vitalize the idea of cancer chemoprevention with Se in the post-SELECT era. We advocate smaller mechanism-driven Phase I/II trials with these next-gen Se to guide and justify future decisions for definitive Phase III chemoprevention efficacy trials.en
dc.identifier10.5152/npa.2016.12709
dc.identifier.citationLÜ J., ZHANG J., JIANG C., DENG Y., Özten N., BOSLAND M., -Cancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges.-, Nutrition and cancer, cilt.68, ss.1-17, 2016
dc.identifier.doi10.1080/01635581.2016.1105267
dc.identifier.pubmed26595411
dc.identifier.scopus84957977658
dc.identifier.urihttps://hdl.handle.net/20.500.12645/3039
dc.identifier.wosWOS:000374779500001
dc.language.isoen
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.titleCancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges.
dc.typeArticle
dspace.entity.typePublication
local.article.journalnameNOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
local.avesis.id49d240ff-2d70-4391-9dc5-d7266eaf8b3d
local.avesis.response2909
local.publication.goal03 - Sağlık ve Kaliteli Yaşam
local.publication.isinternational1
relation.isAuthorOfPublicationcc769c43-7e6f-42b1-96ed-976d661dacec
relation.isAuthorOfPublication.latestForDiscoverycc769c43-7e6f-42b1-96ed-976d661dacec
relation.isGoalOfPublication9c198c48-b603-4e2f-8366-04edcfc1224c
relation.isGoalOfPublication.latestForDiscovery9c198c48-b603-4e2f-8366-04edcfc1224c
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
17-10.1080-01635581.2016.1105267.pdf
Size:
1.07 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Yayınlar - Eserler
Eczacılık Fakültesi